Longitudinal T1 Brain Mapping Reveals Lesion Variability and Disability in Early RRMS

Overview

This study longitudinally quantified T1 relaxation times in brain tissues of early relapsing-remitting multiple sclerosis (RRMS) patients, revealing heterogeneity within white matter lesions (WML) and associations between prolonged T1 components and clinical disability. The findings suggest that T1 mapping can detect microstructural changes not visible on conventional MRI and may serve as a sensitive biomarker for disease progression.

Background

Relapsing-remitting multiple sclerosis (RRMS) exhibits a highly variable disease course, making early prognosis challenging. Conventional MRI detects new or enlarging white matter lesions (WML) but does not fully explain clinical disability. T1-weighted hypointense lesions, or 'black holes,' indicate more severe tissue damage but are assessed qualitatively. Quantitative T1 mapping offers a non-invasive measure of myelin density and microstructural integrity, potentially improving detection of subtle abnormalities in both lesions and normal-appearing brain tissue.

Data Highlights

Seventy-nine recently diagnosed RRMS patients underwent 3-Tesla MRI with T1 mapping at baseline and 1-year follow-up. Twelve age- and sex-matched healthy controls underwent test-retest MRI to assess reliability. WML segmentation and brain tissue classification were performed using FreeSurfer and manual correction. Median T1 values and voxel-wise T1 distributions within WML were calculated to assess heterogeneity and longitudinal changes.

Key Findings

• T1 mapping revealed significant heterogeneity within WML, with varying degrees of T1 prolongation indicating microstructural differences not captured by conventional MRI.
• Prolonged T1 components within WML and other brain tissues increased over the first year following RRMS diagnosis, suggesting progressive microstructural damage.
• Higher volumes of tissue with substantially prolonged T1 correlated with greater clinical disability as measured by the Expanded Disability Status Scale (EDSS).
• T1 prolongation was also detected in normal-appearing white matter and grey matter, indicating widespread pathological changes beyond visible lesions.
• Test-retest reliability of T1 measures in healthy controls was high, supporting the robustness of quantitative T1 mapping as a biomarker.

Clinical Implications

Quantitative T1 mapping provides a sensitive and objective measure of microstructural brain damage in early RRMS, potentially improving prognostication and monitoring of disease progression. Incorporating T1 mapping into clinical protocols may aid in identifying patients at higher risk of disability progression, informing early treatment decisions. Furthermore, T1 mapping could serve as a valuable outcome measure in clinical trials targeting neuroprotection and remyelination.

Conclusion

Longitudinal T1 brain mapping in early RRMS detects microstructural heterogeneity within lesions and normal-appearing tissue that correlates with clinical disability progression. These findings support the utility of quantitative T1 as a biomarker for disease monitoring and prognosis in RRMS.

References

1. FutureMS Study Group 2017-2019 -- Prospective longitudinal cohort of early RRMS patients
2. FreeSurfer v6.0 -- Brain tissue segmentation software
3. FSL FLIRT v6.0.1 -- Image registration tool
4. T1 Mapping Software -- MATLAB implementation for VFA gradient echo T1 quantification